“…However, epidemiological cohorts and clinical trials that generate evidence on disease-specific HRQoL changes rarely incorporate utility measures. In health economic analyses, therefore, disease-specific HRQoL data of cancer patients are often converted to utility scores or used as a proxy to calculate QALYs(McTaggart et al, [2013]).According to our knowledge, the most widely used utility measure, the EQ-5D questionnaire has been reported only in two BC studies so far(Tejido-Sanchez et al, [2014];Li et al, [2014]). Extrapolated utility scores from other conditions with similar health states have been used to estimate QALY gains as little is known on the link between disease-specific HRQoL and preference based health state measures in the field of BC(Kulkami et al, [2009];…”